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ABSTRACT: 
The aggregation of β-amyloid (Aβ) into toxic oligomers is a hallmark of Alzheimer’s disease 
pathology. Here we present a novel approach for the development of peptides capable of 
preventing amyloid aggregation based upon the previous selection of natural all-L peptides that 
bind Aβ1-42. Using an intracellular selection system, successful library members were further 
screened via competition selection to identify the most effective peptides capable of reducing 
amyloid levels. In order to circumvent potential issues arising from stability and protease 
action for these structures we have replaced all L-residues with D-residues and inverted the 
sequence. These retro-inverso (RI) peptide analogues therefore encompass reversed sequences 
that maintain the overall topological order of the native peptides. Our results demonstrate that 
efficacy in blocking and reversing amyloid formation is maintained while introducing desirable 
properties to the peptides. Thioflavin-T assays, circular dichroism, and oblique angle 
fluorescence microscopy collectively indicate that RI-peptides can reduce amyloid load while 
MTT assays demonstrate modest reductions in cell toxicity. These conclusions are reinforced 
using Drosophila melanogaster studies to monitor pupal hatching rates and fly locomotor 
activity in the presence of RI-peptides delivered via RI-TAT peptide fusions. We demonstrate 
that the RI-PCA approach can be used as a generalised method for deriving Aβ-interacting 
peptides. This approach has subsequently led to several peptide candidates to be further 
explored as potential treatments for Alzheimer’s disease. 
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INTRODUCTION 
A vast body of evidence implicates Aβ as a major player in Alzheimer’s Disease (AD) 
(1), with genetic studies revealing abnormal production in cell culture and animal models. Aβ 
aggregation is implicated in neuronal death and impaired memory (2), with a wealth of 
evidence suggesting that amyloid load in AD sufferers does not correlate with disease severity 
(2, 3). The insoluble fibrils that are characteristic of the disease may serve as reservoirs that 
sequester a number of more toxic and soluble oligomeric species. Consequently, targeting Aβ 
via therapeutic intervention has led to numerous inhibition strategies. Rare familial mutations 
that increase Aβ oligomer concentration (e.g. the E22G arctic mutation (4)) have been shown 
to accelerate the onset of AD as a result (4). Many β-sheet breaker (BSB) molecules that block 
or breakdown amyloid fibres have had limited success and in certain cases have been 
counteractive, owing either to increased oligomer production or a failure to accelerate their 
removal (5-11). Therefore, since oligomers as small as dimers have been shown to exhibit 
cytotoxicity (12, 13) molecules effective at lowering amyloid levels may need to either 
sequester fibrils in the insoluble state, or preferably bind Aβ as a small but ultimately non-toxic 
oligomer, possibly even the monomer (14).  
 We have previously used intracellular library screening and selection to identify Aβ 
interacting peptides (15). In this approach, residues 25-35 of Aβ are used as a design scaffold. 
This sequence, along with residues 15-20, is known to form amyloid in isolation (5, 6) and is 
thought to be responsible for instigating Aβ self-association in the parental protein. Many 
amyloid inhibitors have therefore been based upon these regions (5-11) (see also (16) and 
references therein), with many strategies focused on simple modifications such that they retain 
the ability to bind Aβ but prevent amyloid formation by introducing blocking or charged 
groups to these short sequences. For example, Tjernberg et al demonstrated that Aβ16 –20, 
despite forming fibrils itself, binds residues 25–35 of Aβ and prevents fibril formation (5).  
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Soto and co-workers rationally designed proline-containing peptides based on Aβ17–21 (10, 11). 
It was subsequently shown that clearance of large amyloid fibrils can lead to the population of 
smaller more cytotoxic intermediates (17).  Therefore, the search for BSB peptides has been 
hampered by the fact that successful molecules must be capable of preventing the population of 
amyloid oligomers while avoiding the generation of cytotoxic species. In our current approach 
we use an intracellular protein-fragment complementation assay (PCA) selection, which works 
by recombining a split enzyme that is essential for cell survival (15, 18-20). We apply a 
variation on this system whereby the Aβ target is fused at the genetic level to one half of the 
essential enzyme murine dihydrofolate reductase (mDHFR), with a peptide library fused to the 
other half. Following protein expression in the cytoplasm, binding of a library member to Aβ 
reconstitutes mDHFR, leading to bacterial cell growth and colony formation under selective 
conditions. Since the entire process is intracellular, no assumptions are made regarding the 
mechanism of antagonist action or which amyloid states become populated during selection. 
The only prerequisite for success of any given library member is therefore that it must i) bind 
to Aβ and reconstitute mDHFR and ii) prevent Aβ aggregation that has been shown to slow cell 
growth, with E.coli rescued from the toxic effects of aggregation. In addition, the PCA 
approach is predicted to select peptides that are resistant to degradation by bacterial proteases, 
be soluble in solution, and target-specific in the presence of other cytoplasmic proteins. Using 
PCA with an 8000 member library based on Aβ29-35 led to an initial interacting sequence. A 
second library of 160,000 members using this first hit as a design scaffold yielded two further 
novel interacting sequences. These peptides consequently shared no homology to the original 
Aβ29-35 design template. All selected peptides were found to be capable of binding Aβ, 
inhibiting amyloid formation and breaking down preformed fibrils.  
A potential limitation of this previous study was the use of natural unmodified L-
peptides which are susceptible to degradation by mammalian proteases. This was partially 
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addressed by undertaking library selection inside the cytoplasm of E.coli. However, while 
bacterial growth experiments indicated that toxicity was lowered, cytotoxicity experiments 
using mammalian cells suggested that protease protection was not observed when transferring 
to the PC12 cell environment (15). In a continuation of the above study we present data on 
retro-inversed (RI) analogues of these previously selected peptides whereby we have 
substituted the L-amino acids for their D counterparts and reversed the sequence. The D-amino 
acid sequences give a mirror conformation, while the retro-peptides, consisting of the same 
sequence of L-amino acids, leads to a reversal in order. Sequence retro-inversal therefore leads 
to a mimic of the original peptide owing to inversion of the peptide bonds (21, 22). Using this 
approach peptides have been shown to retain the same inhibitory aggregation qualities while 
displaying vastly increased protease resistance (23). For example, rationally designed RI 
peptide inhibitors of Aβ aggregation have previously been derived by appending arginine 
residues to the Aβ16-20 (KLVFF) sequence (24, 25). These peptides were also shown to be 
serum stable and with the addition of a RI cell penetrating peptide fusion were also able to 
cross the blood brain barrier and display significant activity in transgenic mouse models (26). 
In addition, although not an RI approach, mirror image phage display has been used to screen a 
12-mer library against an immobilised D-enantiomer of the Aβ1-42  peptide, with the most 
successful peptide binder replaced by D-amino acids to yield a protease-stable peptide capable 
of binding to the natural L-form of Aβ1-42 (27). The success of these studies further highlights 
the potential for peptide-based therapeutic strategies. 
Here we report upon a novel approach that uses intracellular library screening and 
selection followed by sequence retro-inversal (RI-PCA) as a generalised strategy for creating 
stable peptides capable of antagonising protein-protein interactions (PPI). We have tested the 
effectiveness of peptides using a range of in vitro techniques that report on the amount of fibril 
present. These experiments have been coupled with PC12 neuronal cell-based assays that 
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report on the overall effect of toxicity in the presence of various peptides, as well as in vivo 
studies using drosophila melanogaster, to verify peptide efficacy in the context of a whole cell 
Alzheimer’s disease model organism.  
 
MATERIALS AND METHODS 
PCA and expression vector cloning - PCA has been extensively used to derive PPI antagonists 
of activator protein-1 (18, 19, 28, 29). More recently this has been extended to Aβ interacting 
peptides, where a full description of the methods can be found (15). Briefly, mDHFR was split 
and one half fused to an Aβ25-35 target peptide, and the other half to the library (15). Only target 
binding library members bring two halves of mDHFR into close proximity, render it active, 
and lead to colony formation on M9 selective plates. Trimethoprim is used to selectively 
inhibit bacterial DHFR, thereby ensuring that colonies can only arise as the result of an 
interaction between Aβ and a peptide-library member. The Aβ25-35 gene was synthesized using 
overlap extension PCR and cloned into the pES300d-DHFR2 vector system using NheI and 
AscI restriction sites. 
 
PCA Library construction - Library construction and cloning has been described previously 
(15, 18). Briefly, in the first library, positions 31-33 of Aβ29-35 were completely randomized 
using degenerate oligonucleotides containing NNK codons. NNK was used to encode all 
twenty residues while removing two of three stop codons (30) to create an 8000 member 
library. The second library was designed using the first PCA winner (‘KAT’) as a design 
scaffold. In this case residues 29-30 and 34-35 of KAT were randomized, again using the 
codon NNK, this time to generate a library of 160,000 members. Thus in starting with Aβ29-35 
as an initial design scaffold a completely unrelated sequence was subsequently derived. 
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Competition selection during PCA means that only the most effective 1–2 sequences are 
isolated from the 50–100 Aβ binders that are initially identified during single-step selection. 
 
Aβ Peptide preparation - Aβ1-42 was purchased as a pure recombinant peptide from rPeptide 
(Stratech) and used for all experiments described. Prior to use, the peptide was treated to three 
rounds of dissolution in hexofluoro-2-propanol (HFIP), sonication, drying, dissolution in 
trifluoroacetic acid (TFA), followed by sonication and drying, according to the Zagorski 
protocol (31). Peptide was then aliquoted into appropriately sized batches for subsequent 
assays and dried via lyophilisation before being dissolved in 10mM potassium phosphate 
buffer (pH 7.4) to generate a final concentration of 50µM. Rounds of TFA/HFIP treatment 
were used to ensure that amyloid growth always proceeded from the same monomeric state, 
thus reducing errors in amyloid growth and consequent assay measurements. For the second 
library winners, two versions of each peptide was synthesised: (i) the parental sequence 
including selected residues (L2P1a-RI / L2P2a-RI), and (ii) including additional amino acids 
from restriction sites during cloning into the pES230d vector (L2P1b-RI / L2P2b-RI) (15). See 
Table 1 for all peptide sequences.  
 
Peptide preparation – KAT-RI, L2P1a-RI, L2P1b-RI, L2P2a-RI, L2P2b-RI and both a positive 
control from the literature, iAβ5 (10), and a negative control peptide, TAT-dummy-RI,  were 
obtained by Peptide Protein Research (Fareham, UK) as pure lyophilised peptides. In addition, 
for drosophila melanogaster experiments, TAT-KAT-RI, TAT-L2P1-RI and TAT-L2P2-RI 
were also used. Peptides were weighed using an analytical balance and stock solutions of 1mM 
concentration were subsequently dissolved in ultrapure water. Prior to assay peptides were 
either aliquoted and lyophilised or diluted from stock as required. 
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Thioflavin T Assays - ThT inhibition assays were performed using 50 µM Zagorski treated 
(31) monomeric Aβ1-42 in 100 µl of 10 mM potassium phosphate buffer, pH 7.4, with or 
without each peptide at a concentration of 5µM  (for 1:0.1 molar ratio), 50µM (for 1:1 molar 
ratio), 100µM (for 1:2 molar ratio) and 200µM (for 1:4 molar ratio). In addition, for sub-
stoichiometric experiments 0.5 µM (1:0.01 molar ratio), 50 nM (1:0.001 molar ratio) and 5 nM 
(1:0.0001 molar ratio) were also included to demonstrate progressively reduced activity as the 
peptide dose is increasingly lowered, thus demonstrating a trend of dose dependency. To 
achieve this, sufficient Aβ1-42 was lyophilized, dissolved, and thoroughly vortexed as one 
single batch (for immediate use in all Aβ1-42 target-peptide mixes) to a concentration of 50µM 
in potassium phosphate buffer. Each inhibitor was lyophilized and redissolved in an Eppendorf 
tube to a concentration of 5 µM (1:0.1), 50 µM (1:1), 100 µM (1:2), and 200µM (1:4). Finally, 
a 100 µL aliquot of the target solution was added to each inhibitor to give a total assay volume 
of 100 µL containing 50 µM target and the appropriate inhibitor. The assay mixture was 
vortexed and stored at 37°C for three days to induce aggregation in the presence of each 
inhibitor. The ThT assay solution was prepared from a 25x stock containing 500µM ThT. The 
stock was aliquoted and kept frozen until required. It was then allowed to thaw at room 
temperature for 10min before dilution into 10mM Tris buffer pH 7.4, giving the required 
freshly prepared ThT assay solution containing 20µM ThT in 10mM Tris and buffer at pH 7.4.  
A total of 197.1 µL of the ThT assay solution was then added into 2.9 µL of each 
inhibition/reversal assay mixture, thoroughly vortexed and transferred into an appropriate well 
of the multiplate. The fluorescence of amyloid-bound ThT was measured by florescence 
spectroscopy using a Cary Eclipse fluorescence spectrophotometer; bound ThT exhibits a new 
excitation maxima at 450nm and an enhanced emission maxima at 482nm (32). For the 
inhibition assays, the Aβ1-42 target-peptide mixtures were incubated together on day zero at 
37°C and single ThT readings were taken on day three. For the reversal assays, the target was 
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incubated alone at 37°C for three days before the addition of 100 µL to each lyophilized 
inhibitor. The vortexed Aβ1-42 target-peptide solutions were then incubated at 37°C for a further 
three days, at which single ThT readings were taken. 
 
Circular Dichroism (CD) - Far-UV circular dichroism (CD) spectra were recorded on an 
Applied Photophysics Chirascan CD spectrometer at 20°C. Peptide (10µM in 10mM Potassium 
Phosphate buffer pH 7.4) was added to a 1mm CD cell (Hellma) and spectra recorded over the 
200-300 nm range at a scan rate of 10nm/min with step size of 1nm. Spectra were recorded as 
the average of two scans as raw ellipticity. Spectra for RI-peptides alone were subtracted from 
Aβ1-42 target + peptide spectra, to leave normalised CD spectra accounting for the effect of the 
peptide upon the Aβ1-42.  
 
3-(4,5.Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide (MTT) Cell-Toxicity Assay - 
MTT experiments were undertaken using Rat phaeochromocytoma (PC12) cells to assess the 
effect of the toxicity of Aβ1-42. PC12 cells are known to be particularly sensitive and their use 
in this assay is well established (33). The MTT Vybrant® MTT Cell Proliferation Assay Kit 
(Invitrogen) was used to measure the conversion of the water soluble MTT dye to formazan, 
which is then solubilized, and the concentration determined by a colour change monitored via 
absorbance measurement at 570 nm. The change in absorbance can then be converted to a 
percentage MTT reduction which can be used as an indicator of the PC12 cell health in the 
assay. The assay was performed with 10 µM Aβ1-42 and varying molar ratios of peptide 
corresponding to 1:0.1 (0.1 µM), 1:1 (10 µM), 1:2 (20 µM), 1:4 (40 µM).  PC12 cells were 
maintained in RPMI 1640 +2mM glutamine medium mixed with 10% horse serum, 5% foetal 
bovine serum, supplemented with a 20mg/mL gentamycin. Cells were transferred to a sterile 
96-well plate with 30,000 cells per well and experiments performed in triplicate. Briefly, 
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different concentrations of peptides were screened in the presence of 10 µM Aβ1-42. The 
required volume from peptide and target stock solutions was freeze-dried overnight. The 
freeze-dried peptide and Aβ1-42 target were resuspended in 100% dimethyl sulfoxide (DMSO), 
each at 100x stock concentration (i.e. 1 mM, 2 mM, 4 mM or 10 mM). For example for the 
molar ratio 1:1 a total of 5 µL from each of the resuspended peptide/DMSO and target/DMSO 
was mixed in a well of a 96-well preparation plate, thus giving 10µl of 1:1 mM peptide/Aβ1-42 
target concentration ratio in 100% DMSO. A total of 90 µL of RPMI media was added to the 
10 µL peptide/Aβ1-42 target mixture (100:100 µM peptide/Aβ1-42 target ratio in 10% DMSO). A 
total of 10 µL of the 50:50 µM peptide/Aβ1-42 target mixture in 10% DMSO was then dispensed 
into 90 µL of media/PC12 cells, at final peptide peptide and Aβ1-42 target concentrations of 10 
µM. These were incubated for 24 h at 37 °C, 5% CO2, prior to the addition of the MTT dye. A 
total of 10 µL of the day was added to each well and incubated for a further 4h at 37 °C, 5% 
CO2. A total of 100 µL of the DMSO (stop/solubilisation solution) was then added to each well 
and was allowed to stand for 10 minutes. The absorbance was measured at 570 nm using a 96-
well Versamax tuneable microplate reader. 
 
Oblique Angle Fluorescence Microscopy Experiments - Samples were imaged on a custom 
built oblique angle fluorescence system as described previously (OAF, (15, 34)). The 
excitation and emission wavelengths were 488 nm and 500-605 nm respectively. Although 
both the excitation and emission wavelengths were off peak for ThT, the image quality and 
photobleaching characteristics were excellent. All samples were pre-stained with 10 µM ThT, 
pipetted onto a clean glass slide, air dried and then imaged in KPP buffer supplemented with 
100 mM DTT to further minimize photobleaching. For consistency and cross-correlation, the 
same samples were used for inhibition/reversal imaging as those in ThT and CD experiments. 
In addition, all samples provided for OAF imaging were supplied blind. 
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Drosophila Melanogaster Assays – The effect of RI peptides upon drosophila melanogaster 
was assayed by fusing sequences to the (also retro-inversed) nine residue cell-penetrating 
peptide (CPP), TAT (35-37). In these experiments, flies expressing Aβ1-42 were fed nutrient 
containing either RI-peptides or RI-TAT-peptide fusions (see Table 1) and two key effects 
monitored; i) the speed of pupae hatching in which the cumulative hatching fractions for each 
treatment was monitored relative to a negative control group ii) fly motility using an automated 
fly tracking system to monitor the walking speed of the transgenic flies. In the control group, 
flies typically become immobile as they age over the first 10-15 days of life.    
 
RESULTS 
We have previously undertaken PCA screening on libraries to derive peptides capable of 
clearing Aβ1-42 aggregates and generating significant enhancements in bacterial growth rates 
(15). To produce peptides that retain the ability to bind Aβ1-42 while bringing additional 
properties to the molecule such as stability and protease resistance (23, 38) we have now retro-
inversed these sequences. The RI-PCA derived peptides (Table 1) have been synthesized and 
characterised using a number of methods including ThT dye fluorescence to report on amyloid 
formation, CD to measure global changes in β-sheet content associated with fibril formation, 
and direct imaging using OAF microscopy. These techniques have demonstrated that RI-
peptides retain the ability of the PCA selected parental peptides to prevent aggregation and 
remove preformed fibrils. In addition, MTT cytotoxicity assays undertaken using a neuronal 
PC12 cell line were used to demonstrate that Aβ1-42 toxicity is lowered when bacterially 
selected peptides (which were not effective in MTT experiments (15)) are retro-inversed in 
sequence. To explore cell-based experiments further, we have undertaken studies in which 
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drosophila melanogaster expressing wild-type Aβ1-42 were fed RI-peptides as well as RI-TAT-
peptide fusions to bring cell permeability to these Aβ1-42 interacting compounds.  
 
ThT binding indicates reduced fibril load - To determine the ability of PCA derived peptides 
to either prevent fibril assembly (inhibition) and/or breakdown preformed fibrils (reversal), 
ThT was used as an indicator of the degree to which Aβ1-42 had aggregated into amyloid fibrils. 
In this assay Aβ1-42 was rendered monomeric (31) and redissolved at a concentration of 50 µM 
before being aggregated by incubating without agitation at 37°C. For the inhibition assay, 
peptides were added on day zero, whereas for the reversal assay the peptides were added after 
three days of Aβ1-42 fibril growth. Once incubated together, Aβ1-42 target-peptide solutions were 
tested after three days. In addition to the five RI-PCA derived peptides, the positive control L-
peptide iAβ5 was also included as it is known to perform well in ThT assays and lead to a 
reduction in fibril load (11). Finally a negative control peptide TAT-dummy-RI was included 
to demonstrate no effect on ThT binding and therefore specificity for the PCA-derived 
peptides. Figure 1 shows the results of these experiments at a number of Aβ1-42:peptide ratios 
for each peptide. Experiments were undertaken at stoichiometries of 1:0.0001, 1:0.001, 1:0.01, 
1:0.1, 1:1, 1:2 and 1:4.  
 Inhibition experiments demonstrate that peptides are able to prevent aggregation 
(Figure 1a) with reductions in ThT bound relative to the Aβ1-42 control of up to 80%. During 
these experiments, a concentration dependence was observed as the Aβ:peptide ratio was 
lowered (Figure 1). At increasingly higher stoichiometries this trend was less apparent. For 
example, L2P1a-RI lowered bound ThT by ~30-40% at Aβ:peptide stoichiometries of 1:0.01 of 
greater. Similarly, L2P2b-RI was also able to reduce bound ThT by >40%. RI-peptides 
incubated in the absence of Aβ did not bind ThT, displayed weakly helical CD spectra, and 
were soluble to high concentrations in stock solutions. The lack of concentration dependence 
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for ThT assays at higher molar ratios is likely to be due to signal-to-noise difficulties, as is 
shown by consistently large errors that are typical of this assay. In addition, ThT is known to 
exhibit different fluorescence levels according to the oligomeric state populated (39). Given 
that there are a number of potential intermediates in the growth of Aβ, different fluorescence 
intensities could result. Reassuringly, the all L-residue positive control peptide, iAβ5 (11) 
performed well, providing a reduction of 60-80%, that was lost in a dose dependent manner at 
lower Aβ:iAβ5 ratios. In addition the negative control TAT-dummy-RI peptide had no effect 
over a range of molar ratios, again demonstrating specificity for the PCA-derived sequences. 
RI peptides performed favourably relative to their PCA-derived L-peptide counterparts. 
In the case of reversal experiments (Figure 1b), as was observed previously for the L-
peptide counterparts, more pronounced reductions are observed relative to inhibition 
experiments; over 60% for all peptides tested in all but six instances. At molar ratios of 1:0.1 
reductions of >60% were observed for all peptides. Increasing the molar ratio did not lead to 
improvements in reversal of amyloid in most cases, indicating that a ten-fold sub-
stoichiometric concentration of peptide may be sufficient to reverse fibril formation. As we 
previously reported for parental L-peptides, a progressively reduced activity was observed as 
the peptide dose tended towards zero, demonstrating a dose dependency (15). Experiments on 
RI-peptides in isolation indicate that peptides do not aggregate into fibrils. They do not bind 
ThT and do not generate CD spectra consistent with a β-sheet structure. Again, as predicted 
from the literature, iAβ5 performed well at higher molar ratios, and this effect is lost at lower 
ratios. These results compare favourably with PCA-derived L-peptide counterparts in being 
able to reduce the ThT bound by ~60% (15). Again, the negative control TAT-dummy-RI 
peptide also had no effect over a range of molar ratios.  Errors associated with ThT 
experiments preclude more detailed interpretations from being drawn.  
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CD studies indicate reduced β-sheet content – Owing to the fact that amyloid fibrils are 
predominantly β-sheet, we have used CD as a measure of the global signal upon incubation 
with peptides in inhibition and reversal assays. In these experiments the same aggregating 
samples as used in ThT experiments have been measured to allow for direct comparison 
between experiments. However, CD experiments in which the aggregating all L-residue Aβ1-42 
target is mixed with D-residue containing RI-peptides must be approached with caution; in 
incubating the peptides together with Aβ1-42 it was unknown if a signal at 218 nm caused by the 
RI-peptides might obscure the signal at 218 nm arising from the Aβ1-42 target. Therefore, the 
CD signal of Aβ1-42 and RI-peptides were both measured in isolation. The CD spectra arising 
from these controls could then be accounted for (i.e. CD spectra of Aβ1-42 against [Aβ1-42 + RI-
peptide] – [RI-peptide alone]; Figure 2), allowing the overall loss or gain in β-sheet signal 
exerted by the action of RI-peptide upon Aβ aggregation to be established.  In this assay we 
observe impressive reductions in β-sheet content for all peptides at various molar ratios, 
supporting the ThT data by demonstrating that RI-peptides reduce the global β-sheet content of 
the sample and therefore the amyloid content. In agreement with the ThT data the negative 
control peptide TAT-dummy-RI had little effect on the CD signal demonstrating Aβ specificity 
for the PCA-derived sequences.  
 
ThT and CD experiments demonstrate that RI peptides do not aggregate in isolation - ThT 
experiments and Circular Dichroism spectroscopy experiments undertaken on RI-peptides in 
isolation that have been incubated at 50 µM for three days under conditions identical to 
aggregation assays using Aβ1-42 demonstrate that peptides do not bind significant amounts of 
ThT, and that the CD signal for all peptides (at 0:1) is consistent with that of a random coil or 
weakly helical conformation. They therefore indicate along with computational aggregation 
Page 14 of 38
ACS Paragon Plus Environment
Biochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
15 
 
prediction programs on the L-residue parent peptides (e.g. Waltz (40), Amylpred (41), Pasta 
(42), Zyggregator (43), and Tango (44) that peptides do not form amyloid in isolation. 
 
MTT experiments indicate reduced amyloid toxicity to cells - MTT ((3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide)) cell toxicity experiments were performed using Rat 
phaeochromocytoma (PC12) neuronal-like cells to assess toxicity of Aβ1-42 and the 
preventative effects of the peptides generated in this study. MTT assays (Fig. 4) were 
preformed across Aβ1-42 target:RI-peptide ratios and normalised relative to cells in isolation 
(normalised as 0% death) and cells incubated with Aβ1-42 alone (normalised as 100% death). 
Peptides did not improve cell viability when incubated at 1:0.1. At the increased ratio of 1:1 a 
decrease in toxicity of between ~30 % was observed for all RI-peptides studied. At increased 
molar ratios of 1:2 and 1:4 a decrease in toxicity of approximately 10-20% was observed for all 
RI-peptides studied. This experiment demonstrates a modest but significant reduction in Aβ1-42 
induced toxicity in the presence of RI-peptides. This was more promising than for the PCA 
derived L-peptide parent molecules (15) and more impressive than the iAβ5 peptide which has 
been previously shown to perform poorly in MTT cytotoxicity experiments using the PC12 
cell-line (7). Reassuringly, the TAT-dummy-RI peptide had minimal effect of the viability of 
PC12 cells incubated with Aβ. 
 
Oblique Angle Fluorescence (OAF) Microscopy indicates a reduction in amyloid levels – To 
allow direct comparison, samples used in ThT and CD experiments were also imaged using 
OAF microscopy (34) for both inhibition and reversal experiments. To prevent bias toward any 
one sample the experiment was carried out blind. This technique allows for surface associated 
and stacked aggregates of amyloid fibres to be imaged directly. OAF also permits assessment 
of the amount of protein deposited as amyloid and its morphology. To further quantify the 
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amount of amyloid deposited we analysed the mean fluorescence value for each condition 
using ImageJ (NIH, USA) over a randomly chosen 160x160 pixel
2
 area and found a similar 
correlation. In studying the peptides’ effects on reversal we found KAT-RI, L2P1b-RI and 
L2P2a-RI were the most potent, resulting in the fewest observed fibrils on the surface. Also 
consistent with the reduction in ThT bound, L2P1a-RI and L2P1b-RI appear to have removed 
the vast majority of fibrils present in the solution. Finally L2P2b-RI displays a number of 
deposits that are smaller and of different morphology to the Aβ1-42 sample.  
OAF microscopy data for inhibition experiments demonstrated that fibrils are present in 
iAβ5, L2P1a-RI, L2P1b-RI, L2P2a-RI and L2P2b-RI samples. However the average intensity 
of these fibrils was reduced relative to Aβ1-42. KAT-RI stood out as the one sample with 
reduced fluorescence intensity and no appearance of fibrils on the surface indicating that KAT-
RI reduced the deposition of amyloid. Collectively these data suggest that KAT-RI is most 
effective overall, while L2P1b-RI and L2P2a-RI are also effective at reversal. 
 
Retro-Inverso Peptides Rescue Developmental Delay in a Drosophila Model of Aβ Toxicity - 
Our initial experiments used retinal expression of the Arctic (E22G) variant of Aβ1-42 to screen 
for amelioration of the expected rough eye phenotype.  The flies were treated with RI peptides 
in the food throughout larval development.  Upon eclosion the severity of the phenotype was 
scored by investigators blind to the treatment history.  No differences in the rough eye 
phenotype, as compared to untreated flies, could be detected for any of the peptides (data not 
shown).  We did however notice that some treated flies appeared to hatch either earlier or later 
than normal.  When we formally assessed the hatching times of flies, expressing wild type Aβ1-
42, we found that two RI peptides lacking a TAT sequence led to an increase in the hatching 
time as compared to untreated control flies expressing Aβ1-42 (Fig. 6A, left panel).  In addition 
we saw three significant differences for TAT-containing peptides.  Considering the Aβ1-42-
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expressing flies we found that those treated with the TAT-L2P2-RI peptide hatched 
significantly earlier while those treated with TAT-KAT-RI and TAT-L2P1-RI, which were 
comparable to water-fed controls.  Surprisingly treatment with a poly-gly dummy peptide 
linked to the TAT sequence resulted in a more severe developmental delay as compared to 
untreated flies (Fig. 6B, right panel). This sequence reassuringly demonstrates that the effect of 
improved hatching is sequence specific, with this control sequence having the opposite effect. 
As an additional control, non-transgenic flies were treated with TAT-L2P2-RI and TAT-
dummy-RI peptide; these flies hatched at the same time as control flies treated with water (data 
not shown) suggesting that the effects on development are Aβ-specific. 
 
Retro-Inverso Peptides Promote Locomotor Activity in a Drosophila Model of Aβ Toxicity- 
The expression of Aβ peptides in the nervous system of the fly is known to reduce the walking 
velocity of flies with increasing age.  To determine whether Aβ1-42–expressing flies treated 
with RI peptides might retain their locomotor function for longer.  As we can see from Fig. 7A, 
left panel, when we treated flies with RI peptides lacking a TAT sequence, there were only 
small effects on the walking velocity, particularly for flies younger than 5 days.  Those 
peptides that carry a TAT sequence (Fig 7B, right panel) also increased the walking velocity of 
young Aβ1-42–expressing flies.  In particular flies treated with the TAT-L2P1-RI peptide 
exhibited markedly increased walking velocities. 
 
Retro-inversed peptides have minimal effect on the presence of plaques - Oral administration 
of RI peptides did not alter the pattern of Aβ42 deposits in the Drosophila brain (Figure 8).  
Flies treated with KAT-RI, L2P1-RI, L2P2-RI, TAT-KAT-RI, TAT-L2P1-RI, TAT-L2P2-RI, 
TAT-Dummy-RI and water all appeared to exhibit similar deposits of Aβ-reactive material 
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(arrow, stained with 6E10 antibody), suggesting that although amyloid deposits recognised by 
this antibody have not been abolished, the production of toxic species has been modulated.  
 
DISCUSSION 
The PPI field has long been considered undruggable using conventional small 
molecules, while peptide-based approaches have gained considerable traction in recent years 
(23, 38). This owes to the fact that PPIs feature extended interacting surfaces with many 
points of contact that are too shallow to accommodate traditional small molecule inhibitors, 
making peptides and their mimetics promising candidates for intervention. Peptides often 
form highly specific interactions with their target and many associated barriers (e.g. cell 
permeability and bioavailability) can now be addressed via a number of modification options. 
To develop peptide inhibitors of Aβ amyloidosis, we have combined a Protein-fragment 
Complementation Assay (PCA) approach with semi-rational library design, and PCA 
screening. This has been followed by retro-inversal of the selected peptide sequences to 
identify molecules capable of binding Aβ1-42 and lowering toxicity. The process has been 
iterative; the initial library search used the Aβ29-35 sequence as a design scaffold, and the 
second library design was based on the initial winner, to yield a completely unrelated 
sequence to the parent template. By retro-inversing these PCA library-selected sequences we 
aimed to increase peptide bioavailability while retaining desirable inhibitory properties. Our 
results demonstrate that the inhibitory properties found in the L-peptide templates are retained 
in the RI sequences. For both inhibition and reversal ThT experiments we observed a 
reduction in the ThT-bound to Aβ1-42 upon incubation with RI-sequences. Reassuringly the 
reduction in ThT bound is less at increasingly sub-stoichiometric peptide concentrations, 
demonstrating a dose dependency. ThT data is supported by a large decrease in the global β-
sheet CD signal upon examination of the same samples. These experiments therefore suggest 
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that RI-peptides can bind Aβ1-42 and exert their effect by reducing the amount of the protein 
in amyloid form. The reduction in CD signal was more pronounced than for ThT reflecting 
that the assays measure different outputs. Thus while fibrils are being broken down into 
smaller structures with significantly less β-sheet content, the species that become populated 
are still able to bind ThT, although to a lesser extent than for Aβ1-42 in isolation. In addition, 
as was observed for L-peptides, the reduction in ThT bound is more pronounced for reversal 
experiments, suggesting that RI-peptides are more effective at reversing preformed fibrils 
than preventing amyloid assembly. RI-Peptides in isolation displayed either random coil or 
weakly helical spectra, perhaps indicating a mechanism of binding that involves a structural 
change in the target protein. MTT cytotoxicity data additionally indicate that although at sub-
stoichiometric ratios RI-peptides are effective at reducing β-sheet content and ThT-binding, 
they are ineffective at causing a reduction in Aβ1-42 toxicity. For this to be achieved molar 
ratios of 1:1 or greater are required. This reduction in toxicity is modest (~30% at most), 
suggesting that although populated amyloid species are not toxic to the bacteria in which they 
were selected, the reduction in toxicity is however reduced when transferred to the context of 
a mammalian line. Since bacterial cells harbouring parental L-peptide-DHFR2 fusions have 
demonstrated an improvement in DHFR activity as well as increased bacterial doubling rates, 
this suggests that toxicity reduction is successful within the confines of the selection system. 
One possibility to circumvent this issue and improve outputs from the MTT assay would be to 
use libraries based on existing sequences while transferring the PCA selection to a 
therapeutically relevant neuronal cell line (20). However, testing these RI compounds in 
Drosophila melanogaster has demonstrated that several sequences can go on to improve 
either hatching rates or locomotor activity, with TAT-L2P2-RI being the most striking for the 
former and TAT-L2P1-RI for the latter. Lastly, the presence of comparable brain plaque 
levels for each of the peptides suggests that amyloid deposits recognised by this antibody 
Page 19 of 38
ACS Paragon Plus Environment
Biochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
20 
 
have not been abolished. Interpreting this result alongside fly hatching times and locomotor 
activity data suggests that the production of the toxic Aβ species has been modulated. These 
results compare favourably with ThT, CD, OAF microscopy and MTT studies in 
demonstrating that peptides function by modulating amyloid levels and consequently 
reducing associated cytotoxicity. The RI-PCA approach therefore offers the potential to 
derive protease resistant Aβ-interacting peptides that are capable of lowering the toxicity 
associated with amyloid, which may in turn serve as potential precursors for an Alzheimer’s 
disease treatment.  
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FIGURE LEGENDS 
Figure 1: ThT Inhibition and Reversal Data. The data in a) and b) show the effects of different 
stoichiometries of the peptides KAT-RI, L2P1a-RI, L2P1b-RI, L2P2a-RI, and L2P2b-RI on the 
aggregation of 50µM Aβ1-42 (at three days for the inhibition assay and at six days for reversal 
assay). Molar ratios (Aβ:peptide) are shown at 1:0.0001, 1:0.001, 1:0.01, 1:0.1, 1:1, 1:2 and 1:4 
for each peptide. iAβ5 and TAT-dummy-RI are included as positive and negative controls 
respectively. Errors are given as the standard deviation of all errors at each molar ratio. The 
data show that for the three lowest molar ratios (all sub-stoichiometric; 1:0.01, 1:0.001, and 
1:0.0001) the average reduction in ThT bound was minimal (106% for Inhibition and 89% for 
reversal). In contrast at the three highest molar ratios the reduction in ThT bound was 
significantly greater (58% for inhibition, 38% for reversal). The most effective average molar 
ratio for peptides was 1:0.1 which displayed ThT bound values of 35% and 26% for inhibition 
and reversal, approximating to 71% and 63% less than the average of the three lowest 
stoichiometries respectively. 
Figure 2: Circular Dichroism spectra show i) β-sheet content of RI peptides with Aβ ii) RI 
peptides alone and iii) with RI-peptides subtracted from the combined signal (i.e. ii) – i)). This 
is shown at all molar molar ratios studied for inhibition and reversal conditions. Both 
experiments are undertaken at three days postmix and performed at a concentration 10µM Aβ1-
42. 
Figure 3: Circular Dichroism spectroscopy and ThT experiments undertaken on RI-peptides in 
isolation that have been incubated at 50 µM for three days under conditions identical to 
aggregation assays using Aβ1-42.  
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Figure 4: MTT toxicity assay using Aβ1-42 and selected RI-peptides using different molar ratios 
after 24 hours of incubation. The assay was performed with 10 µM Aβ1-42 and different 
concentrations of inhibitor, for example, 1:0.1 (1 µM ), 1:1 (10 µM), 1:2 (20 µM), 1:4 (40 µM). 
Figure 5: Oblique Angle Fluorescence (OAF) Microscopy data. During reversal experiments, 
Aβ1−42 was grown alone for three days, after which RI-peptide was added at a stoichiometry of 
1:4 and followed by a further three day incubation to assay for peptide induced reversal of 
amyloid deposition. Each sample was then imaged by fluorescence microscopy and panels 
showing representative images obtained. To quantify amyloid deposition the mean grey value 
over a 160x160 pixel area randomly chosen for five separate images is plotted as fluorescence 
intensity. Each data point is normalized to the control iAβ5 peptide by subtraction. Shown are 
a) Inhibition data and b) Reversal data. It can be clearly seen that both KAT and L2P1B are 
strongly inhibitory for this reversal assay. The scale bars represent a distance of 2 µm. Each 
data point was then scaled to overcome the ‘background noise’ by taking Aβ (1:0) as the 
maximum. 
Figure 6: Oral administration of RI peptides suppresses the delayed eclosion associated with 
pan-neuronal expression of Aβ42. A)  As compared to Aβ42 treated with water (control), those 
flies treated with KAT-RI and L2P1-RI showed small but significant suppression of the 
developmental delay (p<0.05). B) Upon fusion with the TAT peptide the potency of the RI 
peptides increased with TAT-KAT-RI (p<0.05) and TAT-L2P2-RI (p<0.001) exhibiting 
significant suppression of delayed eclosion as compared to water (control). Oral administration 
of a dummy RI peptide resulted in significant increase in the delay in eclosion (p<0.05).  
Significance determined by the log-rank test. 
Figure 7: Oral administration of RI peptides suppresses the locomotor deficits associated with 
pan-neuronal expression of Aβ42. A) As compared to flies treated with water (control), flies 
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receiving RI peptides recorded higher walking velocities in the first days of adult life.  The 
rank order of velocities was L2P1>L2P2>KAT>control.  B) Upon fusion with the TAT peptide 
the potency of the TAT-L2P1-RI peptide was particularly enhanced.  The rank order of the 
velocities was similar: L2P1>L2P2>(Dummy>)KAT>control.   
Figure 8: Oral administration of RI peptides did not alter the pattern of Aβ42 deposits in the 
Drosophila brain.  Flies treated with KAT-RI (A), L2P1-RI (B), L2P2-RI (C), TAT-KAT-RI 
(D), TAT-L2P1-RI (E), TAT-L2P2-RI (F), TAT-Dummy-RI (G) and water (H) all exhibited 
similar deposits of Aβ-reactive material (arrow, stained with 6E10 antibody). 
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Table 1: PCA derived retro-inversed sequences and related sequences with retro-inversed 
TAT-fusions to promote intracellular uptake for drosophila melanogaster studies.  
 
 
 
Name Sequence 
KAT-RI                       mltakag-NH2 
L2P1a-RI                       nstaksf-NH2 
L2P1b-RI       pagnstaksfsa-NH2 
L2P2a-RI                       attakvp-NH2 
L2P2b-RI       pagattakvpsa-NH2 
Tat-KAT-RI rrrqrrkkrmltakag-NH2 
Tat-L2P1-RI rrrqrrkkrnstaksf-NH2 
Tat-L2P2-RI rrrqrrkkrattakvp-NH2 
TAT-dummy-RI rrrqrrkkrggggggg-NH2 
iAβ5 LPFFD-NH2 
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Figure 5b 
Reversal experiments at 1:4 Stoichiometry 
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